Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 82
- Registration Number
- NCT00006929
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00005976
- Locations
- 🇺🇸
CentraCare Health Plaza, Saint Cloud, Minnesota, United States
🇺🇸Medcenter One Health System, Bismarck, North Dakota, United States
🇺🇸Altru Cancer Center, Grand Forks, North Dakota, United States
Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 640
- Registration Number
- NCT00002623
- Locations
- 🇳🇱
Ziekenhuis St Jansdal, Harderwijk, Netherlands
🇬🇧Royal Marsden Hospital, Sutton, England, United Kingdom
🇧🇪Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- AGO Study Group
- Target Recruit Count
- 63
- Registration Number
- NCT00032162
- Locations
- 🇩🇪
Universitaetsklinikum Charite, Berlin, Germany
🇩🇪Zentralkrankenhaus, Bremen, Germany
🇩🇪Medizinische Klinik I, Dresden, Germany
Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- California Cancer Consortium
- Target Recruit Count
- 30
- Registration Number
- NCT00033410
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 38
- Registration Number
- NCT00006356
- Locations
- 🇮🇹
Spedali Civili, Brescia, Italy
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 5
- Registration Number
- NCT00025298
- Locations
- 🇮🇹
Ospedale Santa Croce, Cuneo, Italy
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇮🇹Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
- Conditions
- Locations
- 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇨🇦Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
🇮🇹Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano (Milan), Italy
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00042835
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.